menu
    • menu
    [{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"HPAPI","year":"2016","type":"Inapplicable","leadProduct":"Beraprost Sodium","moa":"prostaglandins","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Toray Industries","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"HPAPI","year":"2015","type":"Inapplicable","leadProduct":"Beraprost Sodium","moa":"prostaglandins","graph1":"Nephrology","graph2":"Phase II","graph3":"Toray Industries","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Toray Industries \/ Astellas Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Toray Industries \/ Astellas Pharma"},{"orgOrder":0,"company":"Lung Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Beraprost Sodium","moa":"Prostanoid IP receptor||PTGIR","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Lung Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lung Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lung Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Yonsei University","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Beraprost Sodium","moa":"PTGIR","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Yonsei University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yonsei University \/ Astellas Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Yonsei University \/ Astellas Pharma"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Beraprost Sodium","moa":"PTGIR","graph1":"Nephrology","graph2":"Undisclosed","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Seoul National University Hospital \/ Astellas Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Seoul National University Hospital \/ Astellas Pharma"},{"orgOrder":0,"company":"Toray Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Beraprost Sodium","moa":"PTGIR","graph1":"Nephrology","graph2":"Phase I","graph3":"Toray Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Toray Industries \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Toray Industries \/ Undisclosed"},{"orgOrder":0,"company":"Lung Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Beraprost Sodium","moa":"PTGIR","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Lung Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lung Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lung Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Lung Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Beraprost Sodium","moa":"PTGIR","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Lung Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lung Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lung Biotechnology \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Beraprost Sodium

    Menu

    Beraprost Sodium

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    MARKET PLACE

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Lung Biotechnology

                            Country arrow
                            Neuroscience
                            Not Confirmed

                            Lung Biotechnology

                            Country arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Beraprost Sodium

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension

                            Details : Esuberaprost is a HPAPI drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pulmonary Arterial Hypertension.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 04, 2018

                            Lead Product(s) : Beraprost Sodium

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Astellas Pharma

                            Japan arrow
                            Neuroscience
                            Not Confirmed

                            Astellas Pharma

                            Japan arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Beraprost Sodium

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of Dorner Tablets and Aspirin for Prevention of Arteriosclerosis Progress in Type 2 Diabet...

                            Details : Beraprost is a HPAPI drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetes Mellitus, Type 2.

                            Product Name : Undisclosed

                            Product Type : HPAPI

                            Upfront Cash : Inapplicable

                            June 01, 2016

                            Lead Product(s) : Beraprost Sodium

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Toray Industries

                            Japan arrow
                            Neuroscience
                            Not Confirmed

                            Toray Industries

                            Japan arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Beraprost Sodium

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : Astellas Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TRK-100STP PhaseII Clinical Study -Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis)

                            Details : Beraprost is a HPAPI drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Renal Insufficiency, Chronic.

                            Product Name : Undisclosed

                            Product Type : HPAPI

                            Upfront Cash : Inapplicable

                            June 24, 2015

                            Lead Product(s) : Beraprost Sodium

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : Astellas Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Lung Biotechnology

                            Country arrow
                            Neuroscience
                            Not Confirmed

                            Lung Biotechnology

                            Country arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Beraprost Sodium

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Beraprost-314d Added-on to Tyvaso® (BEAT)

                            Details : Beraprost Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pulmonary Arterial Hypertension.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 26, 2013

                            Lead Product(s) : Beraprost Sodium

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Seoul National University Hospital

                            South Korea arrow
                            Neuroscience
                            Not Confirmed

                            Seoul National University Hospital

                            South Korea arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Beraprost Sodium

                            Therapeutic Area : Nephrology

                            Study Phase : Undisclosed

                            Sponsor : Astellas Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Beraprost Sodium and Arterial Stiffness in Patients With Type 2 Diabetic Nephropathy

                            Details : Beraprost Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Diabetic Nephropathies.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 21, 2013

                            Lead Product(s) : Beraprost Sodium

                            Therapeutic Area : Nephrology

                            Highest Development Status : Undisclosed

                            Sponsor : Astellas Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Lung Biotechnology

                            Country arrow
                            Neuroscience
                            Not Confirmed

                            Lung Biotechnology

                            Country arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Beraprost Sodium

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Multinational, Multicenter, Study to Assess the Efficacy and Safety of BPS-314d-MR in Subjects With Pulmonar...

                            Details : Beraprost Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pulmonary Arterial Hypertension.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 24, 2011

                            Lead Product(s) : Beraprost Sodium

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Toray Industries

                            Japan arrow
                            Neuroscience
                            Not Confirmed

                            Toray Industries

                            Japan arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Beraprost Sodium

                            Therapeutic Area : Nephrology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Pharmacokinetic Study of TRK-100STP in Japanese Patients With Renal Impairment

                            Details : Beraprost Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Kidney Diseases.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 29, 2011

                            Lead Product(s) : Beraprost Sodium

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Yonsei University

                            Country arrow
                            Neuroscience
                            Not Confirmed

                            Yonsei University

                            Country arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Beraprost Sodium

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase IV

                            Sponsor : Astellas Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Effect of Prostaglandin I2 on the Endothelial Cell Function Disorder in Type 2 Diabetes Mellitus Patients

                            Details : Beraprost Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetes Mellitus, Type 2.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 02, 2010

                            Lead Product(s) : Beraprost Sodium

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase IV

                            Sponsor : Astellas Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth